Literature DB >> 3409647

Decreased activity of interleukin-2 inhibitor in plasma of patients with systemic lupus erythematosus.

E J Kucharz1, S Sierakowski, J S Goodwin.   

Abstract

Low levels of plasma interleukin-2 inhibitory activity were found in patients with systemic lupus erythematosus (SLE) compared to normal individuals. The depression of the inhibitory activity was significant in patients with severe and moderate SLE while only a slight decrease was observed in the mild form of the disease.

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3409647     DOI： 10.1007/bf02284062

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN： 0770-3198            Impact factor:   2.980


  24 in total

1.  Abnormalities of delayed hypersensitivity in systemic lupus erythematosus.

Authors:  B H Hahn; K K Bagby; C K Osterland
Journal:  Am J Med       Date:  1973-07       Impact factor: 4.965

2.  Soluble inhibitory factor (SIF) in normal human serum.

Authors:  R L Wolf; J Andreoni
Journal:  Cell Immunol       Date:  1982-03-01       Impact factor: 4.868

3.  Serum IL-2 inhibitor in mice. I. Increase during infection.

Authors:  R Lelchuk; J H Playfair
Journal:  Immunology       Date:  1985-09       Impact factor: 7.397

4.  Interleukin 2 deficiencies in rheumatoid arthritis and systemic lupus erythematosus.

Authors:  N Miyasaka; T Nakamura; I J Russell; N Talal
Journal:  Clin Immunol Immunopathol       Date:  1984-04

5.  Decreased interleukin 2 inhibitor in sera of patients with autoimmune disorders.

Authors:  J Y Djeu; T Kasahara; J E Balow; G C Tsokos
Journal:  Clin Exp Immunol       Date:  1986-08       Impact factor: 4.330

6.  In vivo administration of purified human interleukin 2. I. Half-life and immunologic effects of the Jurkat cell line-derived interleukin 2.

Authors:  M T Lotze; L W Frana; S O Sharrow; R J Robb; S A Rosenberg
Journal:  J Immunol       Date:  1985-01       Impact factor: 5.422

7.  Defective production of interleukin 1 and interleukin 2 in patients with systemic lupus erythematosus (SLE).

Authors:  M Linker-Israeli; A C Bakke; R C Kitridou; S Gendler; S Gillis; D A Horwitz
Journal:  J Immunol       Date:  1983-06       Impact factor: 5.422

8.  Characterization and partial purification of a specific interleukin 2 inhibitor.

Authors:  M Honda; C Chan; E M Shevach
Journal:  J Immunol       Date:  1985-09       Impact factor: 5.422

9.  Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro.

Authors:  L A Rubin; C C Kurman; M E Fritz; W E Biddison; B Boutin; R Yarchoan; D L Nelson
Journal:  J Immunol       Date:  1985-11       Impact factor: 5.422

10.  T cell-specific suppressor factor(s) with regulatory influence on interleukin 2 production and function.

Authors:  M Kramer; U Koszinowski
Journal:  J Immunol       Date:  1982-02       Impact factor: 5.422
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.